News | May 13, 2013

VERITAS Trial Confirms Safety of Live Transmission of TAVR Cases

Live Transmission of TAVR Cases Safety SCAI 2013 Scientific Sessions

May 13, 2013 — Live demonstration, transmission or recording of transcatheter aortic valve replacement (TAVR) has been found feasible and safe, even for the typically high-risk patients who undergo the procedure. Results of the VERITAS late-breaking clinical trial, presented at the SCAI 2013 Scientific Sessions, confirmed via comparison of on- and off-camera case studies that recording procedures did not pose any additional risk or complications to patients. 

The risk and value of live case demonstrations as a tool for physician education has been the subject of debate for some time. Proponents of broadcast or recorded procedures say such education provides valuable insights, helping train physicians in new technology and sharpening their awareness of the intricacies of specific techniques. Some medical societies, however, now discourage and have even considered banning live transmission of cardiovascular procedures due to questions about ethics and patient safety, especially for technologies considered to be high-risk, such as cardiac surgery or for the use of investigational devices. In 2010, several medical societies, including SCAI, published an expert consensus document, stating that data were insufficient to properly assess the risk presented by live dissemination of cardiothoracic surgery and interventions.

The VERITAS trial was designed to assess the safety of transmitting live TAVR cases. TAVR is a minimally invasive procedure approved in late 2011 for marketing in the United States in patients who have severe aortic valve stenosis and are not eligible for open-heart surgical aortic valve replacement. Ron Waksman, M.D., Washington Hospital Center, Washington, D.C., presented the VERITAS results during a late-breaking clinical-trial session here at SCAI.

Researchers recruited 64 patients across six different centers worldwide to undergo live or recorded TAVR, of which 46 patients were matched to a control patient who had almost identical procedures without live or recorded transmission. Matched subjects were of similar age, averaging 83 years; and they had similar valve types, which included two devices: the Edwards Sapien Transcatheter Heart Valve and a device approved for marketing in Europe called the Medtronic CoreValve Transcatheter Aortic Valve. Researchers also matched minimally invasive arterial access sites, either transfemorally (through a small incision in the femoral artery) or transapically (directly through the heart muscle wall without invasive surgery). In both groups, access was guided by catheter-based instruments and advanced imaging.

In VERITAS, patients undergoing live transmitted or recorded treatment experienced longer procedure times, about 129 minutes, versus approximately 101 minutes for matched controls not on camera (p=0.007). Final positioning of the aortic valve device was successful in 100 percent of both the live case and control patients. Four patients in the live or recorded cases group (8.7%) required additional implantation compared with one patient in the non-transmitted group (2.2%). Valve migration or obstruction was not experienced by either group.

Resulting complications were similar in both demonstration and control groups. The rates of death and end-organ failure were the same in both groups (2.2%, p=1). The live transmission group was associated with a lower percentage of complications than the control group for acute kidney injury (4.3% to 2.2%, p=1), post valve heart attack (2.2% to 0%, p=1) and of major and minor vascular complications (6.5% to 13%, p=0.485 and 13% to 23.9%, p=0.283, respectively). None of these variations were found to be statistically significant.

Based on these results, Waksman recommended that the medical community should renew its confidence in live case transmission and conduct it more frequently. He cautioned that live disseminations should be performed only by experienced, high-volume operators.

“Live case transmission is a very effective teaching tool that allows physicians to be informed in a very clear demonstration about degree of disease, complexity of cases and everything that the procedure entails,” Waksman said. “Our recommendation is that live cases should continue as a part of physician education.”

“Transparency is very important in these procedures,” he added. “If you don’t perform them live, you don’t present all of the details and you don’t have complete transparency, which is the primary benefit and power of live case transmissions for our community of physicians and for the public.”

Waksman indicated that further studies may be warranted with larger sample sizes. The VERITAS study was partially supported by the U.S. Food and Drug Administration (FDA).

For more information:

Related Content

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
News | Heart Valve Technology | January 15, 2019
Boston Scientific Corp. and Edwards Lifesciences Corp. announced that the companies have reached an agreement to settle...
The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as a arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital. Dr. Dominick Wiktor. The TEE is from a Philips Epiq system.

The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as an arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital.

Feature | Heart Valve Technology | January 14, 2019 | Allen Atchley, M.D., FACC, The Chattanooga Heart Institute
Mitral regurgitation (MR) is one of the most common types of heart valve diseases in the United States, affecting app
JC Medical Announces First U.S. Treatment With J-Valve TAVR Device
News | Heart Valve Technology | January 07, 2019
January 7, 2019 — JC Medical announced the successful treatment of the first U.S.
Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Technology | Heart Valve Technology | January 02, 2019
Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and Drug Administration (FDA...
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
Overlay Init